Find Academic Supervisors

• Cell Biology
• Molecular Biology
• Pharmacology
• +4 more

Qian Yu is a Research Fellow in the Department of Internal Medicine at Yale University's Yale School of Medicine. Their research focuses on cellular and molecular mechanisms underlying lung injury, inflammatory responses, and therapeutic interventions for respiratory diseases. Key areas include vascular integrity in acute lung injury, pharmacological modulation of inflammation, and drug development targeting lung pathologies. Yu's work also explores lipid transport pathways and WNT signaling in skeletal and metabolic disorders. Their studies integrate experimental models with clinical applications, particularly in evaluating novel compounds for treating lung injuries and cancer. Research interests span cell biology, immunology, and pharmacology, with emphasis on translational medicine. Yu has contributed to understanding ferroptosis in viral lung damage, MAP kinase pathway inhibition in lung injury, and exocytosis mechanisms in cerebral cavernous malformations. Their publications highlight innovations in drug repurposing (e.g., pazopanib for coronavirus treatments) and molecular mechanisms of disease progression. Yu's academic contributions include over 30 peer-reviewed articles, with recent focus on small molecule therapies, extracellular vesicle signaling, and genomic analysis of gliomas. While no awards are explicitly listed, their research has implications for developing new treatments for acute lung injury, cancer, and neurovascular disorders. No advising or grant information is provided in the current profile.

James AshtonView profile

Associate Professor

• Inflammatory Bowel Disease
• Paediatrics
• Big Data
• +2 more

Dr James Ashton is an Associate Professor at the University of Southampton, holding affiliations with the Institute for Life Sciences, BiOmics, Human Genetics and Genomic Medicine, and the Institute of Developmental Sciences. His research focuses on precision medicine for inflammatory bowel disease (IBD), utilizing genomic and big data approaches to transform pediatric patient care through personalized diagnostics and therapeutic strategies. His primary research interests center on Inflammatory Bowel Disease, Paediatrics, Big Data analytics, Genomics, and Nutritional science. This work spans clinical, translational, and basic science domains, with emphasis on developing data-driven tools for disease prediction, stratification, and treatment optimization. Current projects integrate whole exome sequencing, methylome analysis, and machine learning to address critical gaps in pediatric IBD management. Analysis of his 2022-2025 publications reveals a consistent focus on genomic biomarkers (particularly NOD2), pharmacogenomics of thiopurines, and machine learning applications for IBD subtyping. His work leverages large clinical datasets to investigate treatment access disparities, disease burden quantification, and stricturing phenotype prediction, establishing a clear trajectory toward data-informed clinical decision-making in pediatric gastroenterology. Scientific Awards NIHR Advanced Fellowship Dr Ashton actively supervises PhD students including Zachary Green and Fernando Vazquez Lopez in Human Development & Health research. His work receives funding from the European Society for Clinical Nutrition and Metabolism (metabolomics project), Guts UK (PAIR-network development), and the European Society for Paediatric Research (NOD2 analysis), demonstrating sustained competitive grant support for pediatric IBD innovation. As core faculty within Southampton's interdisciplinary research ecosystem, he contributes to multiple collaborative groups including the Institute for Life Sciences and Human Genetics and Genomic Medicine, where his team develops genomic biomarkers and big data frameworks to advance precision medicine implementation in inflammatory bowel disease.

• Hepatology
• Liver Transplantation
• Alcohol-Associated Liver Disease
• +3 more

Jef Verbeek serves as an Assistant Professor at KU Leuven's Faculty of Medicine within the Department of Chronic Diseases and Metabolism. He is affiliated with the Hepatology Research Unit at UZ Leuven (University Hospital Leuven), where he conducts research on liver diseases with particular focus on alcohol-associated conditions and genetic disorders like alpha-1 antitrypsin deficiency. His institutional roles include membership in the Council of the Faculty of Medicine and the Council of the Department of Chronic Diseases and Metabolism as senior academic staff. Verbeek's research primarily centers on alcohol-related liver disease mechanisms, transplantation outcomes, and alpha-1 antitrypsin deficiency. His work explores immunological aspects of liver disease, particularly the role of B cells and immunoglobulins, alongside metabolic factors influencing disease progression. Current projects investigate precision dosing in transplant recipients and the impact of bariatric surgery on liver transplant outcomes. His research combines clinical studies with translational approaches to improve diagnostic methods and therapeutic strategies for complex liver conditions. Analysis of Verbeek's recent publications (2024-2025) reveals a strong focus on alpha-1 antitrypsin deficiency (Pi*ZZ genotype) and alcohol-related liver disease. His work spans biomarker discovery, disease progression monitoring, and clinical management strategies. The publications demonstrate interdisciplinary collaboration across European institutions, with emphasis on longitudinal studies and real-world clinical data analysis. Key themes include immunological mechanisms, genetic influences on disease progression, and the intersection of metabolic factors with liver pathology. Verbeek actively supervises multiple research projects as promotor, including: Dissecting the role of B cells and immunoglobulins in alcohol-associated liver disease (2024-2028) Model-informed precision dosing of tacrolimus in transplant recipients (2022-2027) Liver transplantation for alcohol-related liver disease (2021-2025) DICOTAH study on immune cells in alcoholic hepatitis (2020-2024) SARS-CoV-2 infection in transplant recipients (2020-2023) His teaching responsibilities include multiple courses in gastroenterology and internal medicine at KU Leuven, such as 'Hot Topics in Gastroenterology' and various problem-solving modules in gastroenterology and internal medicine. These courses reflect his clinical expertise and research interests in digestive system disorders and liver diseases.

• Veterinary Anesthesiology
• Cardiovascular Pharmacology
• Sedation Protocols
• +5 more

Danielle E Strahl-Heldreth serves as Clinical Associate Professor in the Department of Veterinary Clinical Medicine within the College of Veterinary Medicine at the University of Illinois Urbana-Champaign. Her academic appointment focuses exclusively on clinical veterinary anesthesiology with active research and teaching responsibilities. Her research program centers on pharmacological interactions in veterinary anesthesia, specifically investigating cardiorespiratory effects of co-induction agents across multiple species. Current work emphasizes dose optimization of etomidate, propofol, and guaifenesin while monitoring critical parameters like heart rate, arterial pressure, and righting reflex. Species-specific protocols for cats with hypertrophic cardiomyopathy, late-term mares, and production animals represent key specialization areas. Methodologically, her studies integrate echocardiography, hemodynamic monitoring, and behavioral assessment to evaluate sedation efficacy and safety. Analysis of her 2023-2025 publications reveals a cohesive research trajectory in veterinary anesthesia pharmacology, with increasing focus on species-specific cardiovascular responses. The work demonstrates strong methodological consistency using controlled experimental designs with precise cardiorespiratory monitoring, while progressively expanding from feline models to equine and ruminant applications. Key emerging themes include drug-sparing techniques to minimize cardiovascular depression and development of species-tailored sedation protocols for compromised patients. Dr. Strahl-Heldreth maintains active clinical engagement through the Veterinary Teaching Hospital, where her research directly informs anesthesia protocols for companion and production animals. Her collaborative network spans multiple veterinary specialties including cardiology, equine medicine, and production animal health, as evidenced by co-authorship patterns across recent publications.

Irati Beltran HernandezView profile

Researcher

• Nanobody-Targeted Photodynamic Therapy
• Cancer Therapeutics
• Molecular Imaging
• +7 more

Dr. Irati Beltran Hernandez is a Researcher in the Cell Biology, Neurobiology and Biophysics group within the Department of Biology at the Faculty of Science, Utrecht University. Her research focuses on advancing nanobody-targeted photodynamic therapy (tPDT) for both human and veterinary oncology applications. Research Interests: Her work centers on targeted cancer therapies, particularly using nanobodies for selective delivery of photosensitizers. She investigates immune activation by photodynamic therapy, tumor spheroid models, EGFR and HER2 targeting, and translational applications in companion animals. Her research bridges molecular imaging, drug delivery, and immunotherapy. Publication Trends: Over the past five years, her publications demonstrate a strong trajectory in nanobody-based therapeutics, with increasing focus on immune modulation, antimicrobial applications, and cross-species translation. Her work combines preclinical models with clinical insights, aiming for real-world therapeutic impact. Scientific Awards: No scientific awards are listed in the provided information. Advising and Grants: While no students or grants are explicitly mentioned, her role as a PhD graduate and active researcher suggests involvement in collaborative projects and mentorship within the research group led by Prof. S. Oliveira. Labs and Teams: She is part of the Biodynamics and Biocomplexity research theme at Utrecht University, working in a multidisciplinary environment focused on cellular and molecular mechanisms in disease and therapy.

• Photonics
• Optical Fiber Technology
• Photonic Crystal Fibers
• +12 more

Stefano Selleri is a Full Professor in the Department of Engineering and Architecture at the University of Parma, Italy. He holds the academic rank of Professore di I fascia and teaches courses such as Electromagnetic Fields, Guided Propagation, Microwaves, and Photonics across undergraduate and graduate programs in Electronics, Telecommunications, and Automotive Engineering. He also teaches Electromagnetic Fields at the Medicine and Surgery Faculty, showcasing his interdisciplinary reach. Laurea (M.Sc.) in Electronics Engineering, University of Bologna, 1991 (magna cum laude) Ph.D. in Information Technology, University of Parma, 1995–1997 His research is centered on photonics and electromagnetic theory, with a focus on photonic crystal fibers, fiber lasers, optical amplifiers, nonlinear optics, and Radio over Fiber systems . He has led major European projects including ALPINE (FP7) on industrial fiber lasers for photovoltaic scribing and PUMA on pulsed fiber lasers. His work combines theoretical modeling (Finite Element Method, Beam Propagation Method) with experimental validation, particularly in fiber characterization and near-field optical microscopy. He has also contributed to optical sensing for DNA hybridization and structural health monitoring. The recent publications reflect a growing interdisciplinary trend, merging photonics with biomedicine and advanced manufacturing. Themes include SERS-based cancer detection, whispering gallery mode sensors in silk, and two-photon polymerization for microneedles—highlighting a shift toward biophotonics and microfabrication while maintaining core expertise in optical materials and laser systems. Stefano Selleri has been actively involved in academic service, serving on technical committees and chairing sessions at top conferences like CLEO/Europe and OSA Topicals. He is a reviewer for leading journals including Optics Express , IEEE Photonics Technology Letters , and Journal of Lightwave Technology . He has supervised numerous M.Sc. and Ph.D. students, including M. Fuochi, A.H. Bouk, F. Poli, L. Rosa, and current doctoral candidates Michele Sozzi and Alessandro Candiani. His lab activities include the TECAL Laboratory and development of a scanning near-field optical microscope. He also founded the academic spin-off Net Integra Consulting for RF services.

Matthew SchipperView profile

Professor

• Biostatistics
• Cancer research
• Radiation oncology
• +5 more

Matthew Schipper is a Professor in Radiation Oncology and Director of the Division of Biostatistics and Bioinformatics at the University of Michigan School of Public Health. He also holds a Research Professor appointment in the Biostatistics department. Dr. Schipper works to develop and apply statistical methods to improve the quality and length of life for patients with cancer or other illnesses. His research focuses on: Clinical trial design Data integration for prognostic models Statistical methods for personalized medicine Radiation therapy optimization Clinical decision-making tools He is particularly interested in building predictive models for the efficacy and toxicity of treatment that can inform optimal treatment decisions for individual patients. These models are implemented in web apps to facilitate ease of clinical use. Dr. Schipper has published extensively on these topics, with recent publications covering utility-based approaches to dose selection, life expectancy calculators for prostate cancer patients, improved designs for small sample clinical trials, predictors of pneumonitis after radiotherapy, Bayesian dose-finding methods, evaluation of predictive model performance with missing data, and the use of intermediate clinical endpoints in prostate cancer research.

Marc LabriffeView profile

Associate Professor

• Pharmacometrics
• Machine Learning in Clinical Pharmacology
• Transplantation Medicine
• +3 more

Marc Labriffe is an Associate Professor and Hospital Practitioner at University of Limoges , affiliated with the Faculty of Medicine and Pharmacy . His research focuses on Pharmacometrics , leveraging Machine Learning and Population Pharmacokinetics to advance Personalized Medicine in Transplantation . Key themes include Drug Exposure Prediction , Toxicology , and Clinical Research . Roles: Associate Professor, Hospital Practitioner (MCU-PH) Institution: University of Limoges, Faculty of Medicine and Pharmacy Research Interests center on optimizing drug dosing through Pharmacokinetic Modeling , Bayesian Estimation , and Multi-Scale Analysis of local drug effects. His work bridges Clinical Pharmacology and Artificial Intelligence , particularly in Antibiotic and Immunosuppressant Therapy for transplant recipients. Recent Publications highlight machine learning applications for predicting drug exposure ( daptomycin, tacrolimus, ganciclovir ), analyzing Urinary Proteomics in kidney transplants, and developing Pharmacometric Tools for EU pharmaceutical legislation. Articles span 2020-2025 , emphasizing Drug Safety , Algorithm Explainability , and Clinical Decision Support Systems .

Vincent LamirandView profile

Lecturer

• Radiation Detection
• Instrumentation
• Reactor Physics
• +7 more

Vincent Lamirand is a Lecturer and Tenured Scientist at École polytechnique fédérale de Lausanne (EPFL), working within the School of Basic Sciences, Institute of Physics, and Laboratory for Reactor Physics and Systems Behaviour (LRS). He serves as Program Manager of Experimental Research and Deputy Head of LRS Nuclear Facilities, overseeing experimental activities at the CROCUS experimental reactor and LOTUS cavity. Additionally, he is one of four Scientific Staff Members at the School Assembly, Basic Sciences Faculty Council, and Institute of Physics Council. Dr. Lamirand's educational background includes: PhD in Nuclear Physics from UJF Grenoble 1 (France), 2011 Master Degree in Physics, specializing in Subatomic Physics from UCB Lyon 1 (France), 2008 Bachelor Degree in Physics from UCB Lyon 1 (France), 2006 Dr. Lamirand's research focuses on experimental reactor physics, with emphasis on radiation detection, instrumentation, and measurement techniques for nuclear systems. His work spans neutron and gamma noise analysis, reactor kinetics parameter determination, and high-resolution flux mapping in zero-power reactors. He has pioneered the development of miniature neutron detectors and 3D core-mapping systems like SAFFRON, enabling unprecedented spatial resolution in reactor measurements. His research addresses fundamental questions in reactor physics while providing validation data for advanced simulation codes. His recent publication trend shows a strong focus on neutron and gamma noise analysis in zero-power reactors, particularly through the CORTEX project. He has developed novel methodologies for transfer function determination, uncertainty quantification, and prompt decay constant measurements. His work bridges experimental reactor physics with computational methods, providing valuable validation data for high-fidelity transport codes. The PETALE and BLOOM experimental programs demonstrate his commitment to nuclear data validation, particularly for stainless steel reflectors. Dr. Lamirand actively mentors students at all levels, supervising PhD candidates, Master's theses, semester projects, and internships. His advising spans experimental design, data analysis, and computational methods in reactor physics. While specific grant information isn't detailed in the provided text, his extensive publication record and leadership in major experimental programs like CORTEX, PETALE, and BLOOM suggest significant research funding support. He leads experimental work at the CROCUS zero-power research reactor, operating the LOTUS cavity and developing advanced instrumentation like the SAFFRON 3D core-mapping system with 160 miniature detectors. His laboratory focuses on high-precision measurements for reactor physics validation, nuclear data improvement, and innovative monitoring techniques for nuclear facilities.

Timothy P. HoferView profile

Professor

• Quality of care measurement
• Health services research
• Medical overuse and deintensification
• +3 more

Timothy P. Hofer is a Professor of Internal Medicine at the University of Michigan Medical School and serves as Associate Director for Analytic and Information Resources at the VA Center for Practice Management and Outcomes Research in Ann Arbor. He is also a core faculty member of the National Clinical Scholars Program at Michigan and a member of the Institute for Healthcare Policy and Innovation. Education MD – University of California, School of Medicine, 1985 Internal Medicine Residency – University of California, San Francisco, 1989 Research Interests Dr. Hofer’s work centers on measuring and improving the quality of care for complex patients. He explores methodological and practical challenges in profiling quality and how measurement informs policy initiatives targeting medical error reduction and pay-for-performance systems. Specific interests include adequacy of risk adjustment, socio-economic predictors of utilization, and influences of patients, providers, and organizations on performance indicators. Current projects address: Reducing medical overuse through deintensification of services Quality measurement in complex patients Organizational effects on cancer care quality and treatment decision-making Physician implicit review as a quality measure Multilevel organizational structures Quality improvement for diabetes and chronic diseases Scientific Awards No specific awards are listed in the provided text. Mentoring & Grants Dr. Hofer is designated as “Available to mentor” and devotes significant effort to mentoring trainees in the National Clinical Scholars Program, teaching advanced analytic methods, and leading quality-of-care research projects. Labs & Teams He is affiliated with: VA Center for Practice Management and Outcomes Research University of Michigan Institute for Healthcare Policy and Innovation Global REACH Caswell Diabetes Institute MExperts–Center for Global Health Equity

• Pharmacometrics
• Therapeutic Drug Monitoring
• Precision Dosing
• +2 more

Erwin Dreesen is a tenure-track Lecturer at KU Leuven's Faculty of Pharmaceutical Sciences, affiliated with the Department of Pharmaceutical and Pharmacological Sciences. He leads the Clinical Pharmacology and Pharmacotherapy unit and holds memberships in KU Leuven's iSi Health Institute (physics-based modeling) and Leuven One Health Institute. His committee roles include the Research Ethics Committee UZ/KU Leuven and Faculty Councils. His research specializes in pharmacometrics , therapeutic drug monitoring , and precision dosing , with projects spanning: Model-informed dosing of immunosuppressants in transplant patients Antimicrobial optimization in critical care Geriatric pharmacokinetics Biologics for inflammatory diseases He coordinates 10+ active grants (2021-2029) as promoter/co-promoter, including studies on tacrolimus dosing, crizanlizumab for sickle cell disease, and antimicrobial strategies. Recent publications (2022-2025) demonstrate: Advanced pharmacometric modeling techniques Focus on clinical applications in IBD, antifungal therapy, and geriatrics Emphasis on personalized dosing algorithms and therapeutic monitoring He teaches courses including Pharmacometrics, Drug Development, Thesis Supervision, and Research Methodology.

Kim BrøsenView profile

Professor

• Pharmacokinetics
• Pharmacogenetics
• Drug Metabolism
• +3 more

Kim Brøsen is Professor of Clinical Pharmacology in the Department of Health Services Research at the University of Southern Denmark. Since 1995 he has led research into pharmacokinetics and pharmacogenetics, focusing on genetic determinants of drug metabolism and transport. Education: 1988 – Dr.med. in Clinical Pharmacology, Faculty of Health Sciences, Odense University 1981 – Cand.med., University of Copenhagen Research Interests: Professor Brøsen’s core research area is pharmacokinetics , with particular emphasis on genetic polymorphisms affecting hepatic drug metabolism (e.g., CYP2D6 and CYP2C19) and, more recently, on genetic control of drug transport across cellular membranes . These investigations bridge basic pharmacology and clinical applications, underpinning personalized medicine strategies. Across more than 380 peer-reviewed publications, his recent work has concentrated on population pharmacokinetic modelling of tacrolimus in kidney transplant patients, the influence of antibiotics on P-glycoprotein-mediated drug transport, and metformin pharmacogenomics. These studies collectively advance understanding of variability in drug response and inform evidence-based dosing algorithms. Scientific Awards: BCPT Nordic Prize in Pharmacology and Toxicology (2022) EACPT Lifetime Achievement Award (2022) PhD Supervision & Mentoring: Professor Brøsen has formally supervised at least four PhD students to completion and continues to mentor junior researchers within his department’s clinical pharmacology group. Collaborative Networks & Labs: His research is embedded in an extensive international collaboration network spanning Europe and North America, reflected in multi-centre pharmacokinetic and pharmacogenetic trials. The department hosts state-of-the-art analytical and modelling facilities supporting translational pharmacology research.

• Statistical Modelling
• Pregnancy Complications
• Data Mining
• +5 more

Dr. Shalem Leemaqz is a Postdoctoral Fellow and adjunct staff at the Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide. He maintains dual research appointments as a postdoctoral researcher at the Pregnancy Health and Beyond (PHaB) Lab at the College of Medicine and Public Health, Flinders University, and as a statistician at South Australian Health and Medical Research Institute. With a background spanning Mathematics/Statistics and Electronic Systems Engineering, Dr. Leemaqz brings expertise in computer architecture, machine learning techniques, and programming (particularly R statistical programming) to medical research. His primary research focus involves developing statistical models to predict pregnancy complications through advanced mathematical and data mining approaches for high-dimensional data analysis. During his PhD (2010-2015) at the University of Adelaide, he pioneered a novel tiered modeling approach that classifies low-prevalence outcomes into risk levels, which was applied to develop screening tools for preeclampsia, preterm birth, intrauterine growth restriction, and gestational diabetes. Dr. Leemaqz's recent scholarly output (2023-2025) demonstrates significant contributions across multiple domains including pregnancy complications, placental biology, and transgender health research. His work consistently applies sophisticated statistical methodologies to address complex medical questions, with a particular emphasis on developing flexible algorithms for low-prevalence disease prediction. His research aims to create screening tools that classify patients into three risk levels to enable targeted interventions improving maternal and child health outcomes. Dr. Leemaqz is deeply committed to integrating rigorous statistical methodology with clinical medical research. His collaborative approach bridges statistics, bioinformatics, and clinical medicine to develop integrated methods for analyzing and combining genomic data with clinical information, ultimately advancing precision medicine approaches in pregnancy care.

Tufia C. HaddadView profile

Professor

• Breast Cancer
• Experimental Therapeutics
• Clinical Trials
• +7 more

Dr. Tufia C. Haddad is a Professor of Oncology at Mayo Clinic College of Medicine and Science, serving as a Consultant in the Division of Medical Oncology within the Department of Oncology. She holds leadership positions as Chair of Practice Innovation and Platform at the Mayo Clinic Comprehensive Cancer Center and Medical Director of Care at Home at the Center for Digital Health. With expertise spanning clinical oncology, research, and digital health innovation, Dr. Haddad directs her efforts toward transforming cancer care delivery through technology-enabled solutions while maintaining an active clinical practice focused on breast cancer. MD from Creighton University School of Medicine (2001) Residency in Internal Medicine at Mayo Clinic College of Medicine and Science (2004) Fellowship in Hematology, Oncology and Transplantation at University of Minnesota (2007) Dr. Haddad's research program centers on experimental therapeutics for breast cancer, particularly drug-resistant disease, with significant contributions to phase I/II clinical trial development and biomarker identification. Her work bridges traditional oncology with digital health innovation, exploring how connected health technologies and artificial intelligence can transform cancer care delivery. She has developed novel approaches to optimize endocrine therapy in breast cancer and has investigated mechanisms of resistance to targeted therapies. Her research extends to breast cancer survivorship, where she has pioneered technology-enabled models for post-treatment care. With 99 published research outputs, Dr. Haddad's scholarly work demonstrates consistent productivity with 11 publications in 2024 alone. Her research spans clinical trials, molecular mechanisms of drug resistance, digital health applications, and breast cancer survivorship. She has led significant grant-funded projects including a Congressionally Directed Medical Research Programs award targeting fatty acid synthase in drug-resistant breast cancer and National Cancer Institute-funded research on Aurora-A kinase. Multiple 'Top Performer' awards from Mayo Clinic (2020, 2022, 2024, 2025) HIMSS Future50 Clinical Leader (2021) Innovation Award from Mayo Clinic Midwest Clinical Practice Committee (2019) Multiple Excellence in Teaching Awards (2013, 2014, 2018) Best Doctors recognition by Minnesota Monthly (2015) Dr. Haddad mentors medical students, residents, and fellows while leading multiple research initiatives through her roles at the Mayo Clinic Comprehensive Cancer Center. She serves on the Health Care Delivery Scientific Program Committee of the American Society of Clinical Oncology and contributes to national efforts to transform cancer care delivery. Through her leadership in digital health innovation, she has developed remote patient monitoring programs and structured data capture systems that enhance cancer care quality and accessibility. As Director of the Practice Innovation and Platform component at the Mayo Clinic Comprehensive Cancer Center, Dr. Haddad leads initiatives that integrate cutting-edge technology with clinical care, focusing on decentralized clinical trials, connected health solutions, and artificial intelligence applications in oncology. Her work bridges the gap between traditional cancer treatment and the digital future of healthcare delivery.

• Sustainable energy systems
• Green technology
• Bioenergy and Biofuels
• +4 more

Professor Kevin McDonnell is a faculty member at University College Dublin's School of Agriculture and Food Science, holding the position of Professor in Biosystems Engineering. He has been affiliated with UCD since 1996, progressing from a PhD student to his current role. His research focuses on sustainable energy systems, bioenergy, crop production, and precision agriculture. Key contributions include developing biorefinery systems, optimizing agricultural waste utilization, and advancing technologies for energy efficiency. Education: B.Agr.Sc (UCD, 1991), M.Eng.Sc (UCD, 1993), PhD (UCD, 1996). Professional roles include Senior Lecturer (2012–present), College Lecturer (2002–2012), and Postdoctoral Researcher (1997–2000). He has advised on EU policies and environmental regulations, including roles with the EPA and EU COST Action E31. Research interests span mechanization systems, precision agriculture, and sustainable energy. He leads projects on bioenergy, crop production, and environmental impact assessments. His awards include the Fulbright TechImpact Scholarship (2019), Environmental Innovation Award (2011), and recognition at international forums like the UN Food Systems Summit (2021). Teaching responsibilities include coordinating modules on crop technology, sustainable energy systems, and organic agriculture. He has received grants for initiatives like the AgRefine program (2019–2024) and OPTI-BC (2016–2022). Active in professional associations like the International Society of Precision Agriculture and ASABE. Labs/Teams: Involved in interdisciplinary teams focusing on biorefinery optimization, agricultural machinery, and renewable energy integration. His work bridges academic research with industry applications, emphasizing sustainability and innovation.